RIVM to play greater role in tuberculosis control The Committee for Practical Tuberculosis Control (CPT) will be transferred per 1 January 2022 to the National Institute for Public Health and the Environment (RIVM) after a period of 70 years with KNCV Tuberculosis Foundation.
Launch of the European project RISK-HUNT3R The new Horizon 2020 project RISK-HUNT3R: RISK assessment of chemicals integrating HUman centric Next generation Testing strategies promoting the 3Rs was launched on 1 June.
Largest drop in number of tuberculosis cases in the Netherlands in fifty years Last year, the incidence of tuberculosis (TB) in the Netherlands fell sharply. The 17% drop is the largest in fifty years. In 2020, 623 cases were notified compared to 754 in 2019.
A decrease in the number of tuberculosis patients in the Netherlands In 2019, the number of people with tuberculosis (TB) in the Netherlands decreased to 759. This is 5 per cent less than in 2018, when 797 were reported.
Environmental radioactivity in the Netherlands : Results in 2017 RIVM reports annually on the level of radioactivity that occurs under normal circumstances in the environment and food.
iGEM meetup for teams and supervisors The best synbio projects, including iGEM teams, have one thing in common: cutting edge science in the light of carefully considered societal needs.
Slightly more tuberculosis patients in the Netherlands The key figures of the National Institute for Public Health and the Environment (RIVM) show that in 2018 there were 806 TB patients in the Netherlands. This is 3 percent more than in 2017 (784).
Young people who use screens before sleeping have more sleep problems Young people (13-18 years) who use light-emitting screens daily in the hour before going to sleep have more sleep problems.
Strong decline of tuberculosis in the Netherlands The number of tuberculosis (TB) patients in the Netherlands decreased considerably in 2017. From 887 patients in 2016 to 787 in 2017.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.